Straits Times Index
3,090.31 +17.32 (+0.56%) S&P 500
4,594.63 +26.83 (+0.59%) Dow
36,245.50 +294.61 (+0.82%) Nasdaq
14,305.03 +78.81 (+0.55%) Bitcoin USD
39,574.11 +804.04 (+2.07%) CMC Crypto 200
802.76 +11.20 (+1.41%)
AZN Jan 2025 65.000 put
| Previous close | 5.55 |
| Open | 5.55 |
| Bid | 5.15 |
| Ask | 5.30 |
| Strike | 65.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.55 - 5.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 412 |
ReutersAstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.
- Reuters
UPDATE 1-AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.
- Financial Times
AstraZeneca ties up with AI biologics company to develop cancer drug
AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug discovery. The collaboration aims to harness Absci’s AI technology for large-scale protein analysis to find a viable oncology therapy — a leading focus of Anglo-Swedish drugmaker AstraZeneca. The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them.
